A Phase 3 interventional study of Guselkumab in Crohns Disease, sponsored by Janssen Pharmaceutical K.K.. Completed at 25 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.
Among the 13 studies testing guselkumab in Crohn Disease, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 8 in phase 3, and was the 2nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 196 across the 13 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
63 studies in Crohn Disease by Johnson & Johnson: 16 open now, 23 under way, 10 of them phase 3. Of 38 finished, 16 (42%) have results posted.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 34th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 in phase 3, and was the 37th registered.
Johnson & Johnson’s Crohn Disease studies by the year they started, since 1995.
5 of the studies testing guselkumab in Crohn Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT07310095Xian-Janssen Pharmaceutical Ltd.A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | 2027-09-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies testing guselkumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
Drug: Guselkumab
Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Also known as: CNTO1959
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AEs (TEAEs) were AEs with onset during the intervention phase or that were a consequence of a pre-existing condition that had worsened since baseline. All TEAEs including serious and non-serious AEs were reported.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Number of participants with TESAEs were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)
Number of participants with TEAESI was reported. Active tuberculosis (TB) or malignancies were considered as TEAESIs. TEAESIs were AESIs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Treatment-emergent Abnormalities in Hematology Laboratory Parameters
Number of participants with treatment-emergent abnormalities in hematology laboratory parameters were reported. Laboratory tests included in hematology were hemoglobin, lymphocytes, neutrophils, platelet count, Total WBC (white blood cell) Count. National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory Parameters
Number of participants with treatment-emergent abnormalities in chemistry laboratory parameters were reported. Laboratory parameters included in clinical chemistry were albumin, corrected calcium, creatinine, glucose, potassium, sodium. NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With TEAEs of Infections
Number of participants with TEAEs of infections were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With TEAEs of Injection-site Reactions
Number of participants with TEAEs of injection-site reactions were reported. A significant injection-site reaction was defined as an adverse reaction that was manifested through 1 or more of the following symptoms: significant bruising, erythema, hemorrhage, irritation, pain, pruritus at the site of injection. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With TEAEs Temporally Associated With Infusion
Number of participants with TEAEs temporally associated with infusion were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent
TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. The Columbia-suicide severity rating scale (C-SSRS) defined was 5 subtypes of suicidal ideation and 4 possible suicidal behaviors, as well as non-suicidal self-injurious behavior and completed suicide. The C-SSRS was an investigator-administered questionnaire: 1) No suicidal ideation or behaviors (including self-injurious behavior without suicidal intent): No further action was needed; 2) Suicidal ideation levels 1-3 or non-suicidal self-injurious behavior; participant risk is assessed by the investigator. 3) Suicidal ideation levels 4 or 5 or any suicidal behavior: participant risk assessed and referral to a mental health professional. If no events qualify for scores of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicated greater severity.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs
Number of participants with clinically significant treatment-emergent abnormalities in vital signs were reported. Vital signs included weight, pulse rate, temperature, respiratory rate, systolic blood pressure, and diastolic blood pressure. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
Time frame: From baseline (Week 0) up to Week 48
Number of Participants With Concomitant Medications for Crohn's Disease
Number of participants with concomitant medications for Crohn's disease were reported.
Time frame: From screening (Week -8) up to Week 48
Number of Participants With Clinical Response Through Week 48
Number of participants with clinical response through Week 48 were reported. Clinical response was defined as a greater than or equal to (\>=) 100-point reduction from baseline in CDAI score or CDAI score less than (\<) 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Number of Participants With Clinical Remission Through Week 48
Number of participants with clinical remission through Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission Through Week 48
Number of participants with PRO-2 remission through Week 48 were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48
Change from baseline in SES-CD score at Week 48 were reported. The SES-CD score was used to evaluate endoscopic improvement. The SES-CD was based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for the narrowing component which only attain a maximum total score of 11 because, the presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: Baseline (Week 0) and Week 48
Serum Concentation of Guselkumab
Serum concentration of guselkumab were reported.
Time frame: Predose at Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 1 hour post dose at Weeks 0, 4, 8
Number of Participants With Anti-Guselkumab Antibodies Through Week 48
Number of participants with anti-guselkumab antibodies through Week 48 were reported.
Time frame: From Week 0 through Week 48
Number of Participants With Neutralizing-Guselkumab Antibodies Through Week 48
Number of participants with neutralizing-guselkumab antibodies through Week 48 were reported.
Time frame: From Week 0 through Week 48
Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration
Change from baseline in inflammatory PD marker of CRP concentration were reported.
Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Change From Baseline in Inflammatory PD Marker: Fecal Calprotectin (FC) Levels
Change from baseline in inflammatory PD marker of FC levels were reported.
Time frame: Baseline (Week 0), Weeks 4, 8, 12, 24, and 48
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
Change from baseline in CDAI score at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: At Week 48
Number of Participants in Clinical Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
Number of participants in clinical response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: At Week 48
Number of Participants in Clinical Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
Number of participants in clinical remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: At Week 48
Number of Participants in Endoscopic Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
Number of participants in endoscopic response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: At Week 48
Number of Participants in Endoscopic Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
Number of participants in endoscopic remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: At Week 48
Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) Through Week 48 Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline
Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) through Week 48 among participants receiving oral corticosteroids other than Budesonide at baseline were reported.
Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Number of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
Number of participants not receiving concomitant corticosteroids at Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
Time frame: At Week 48
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
Number of participants not receiving concomitant corticosteroids for at least 30 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
Time frame: Up to Week 48
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
Number of participants not receiving concomitant corticosteroids for at least 90 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
Time frame: Up to Week 48
Number of Participants With Clinical Response Through LTE Phase
Number of participants with clinical response through LTE phase were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Clinical-biomarker Response Through LTE Phase
Number of participants with clinical-biomarker response through LTE phase were reported. Clinical-biomarker response was defined as clinical response based on CDAI score and \>=50% reduction from baseline in CRP or FC. Clinical response: a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug\[s\] and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Clinical Remission Through LTE Phase
Number of participants with clinical remission through LTE phase were reported. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Endoscopic Response Through LTE Phase
Number of participants in endoscopic response through LTE phase were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score \<=2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Endoscopic Remission Through LTE Phase
Number of participants in endoscopic remission through LTE phase were reported. Endoscopic remission was defined as an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing omponent which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Endoscopic Healing Through LTE Phase
Number of participants With endoscopic healing through LTE phase were reported. Endoscopic healing was defined as the absence of mucosal ulcerations.
Time frame: Weeks 96, 144, 192, and 240
Change From Baseline in SES-CD Score During LTE Phase
Change from baseline in SES-CD score during LTE phase were reported. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: Baseline (Week 0), 96, 144, 192, and 240
Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE Phase
Number of participants with PRO-2 remission during LTE phase were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
Time frame: Weeks 96, 144, 192, and 240
Number of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study
Number of participants with any Crohn's Disease-related hospitalizations and/or surgeries during the study were reported.
Time frame: From Week 0 up to final efficacy visit for each participant (up to Week 248)
Serum Guselkumab Concentrations During LTE Phase
Serum guselkumab concentrations during LTE phase were reported.
Time frame: Predose at Weeks 96, 144, 192, and 240
Number of Participants With Anti-Guselkumab Antibodies During the Study
Number of participants with anti-guselkumab antibodies during the study were reported.
Time frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
Number of Participants With Neutralizing Antibodies to Guselkumab During the Study
Number of participants with neutralizing-guselkumab antibodies during the study were reported.
Time frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE Phase
Change from baseline in inflammatory PD marker of CRP concentration during LTE phase were reported.
Time frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
Change From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE Phase
Change from baseline in inflammatory PD marker of FC levels during LTE phase were reported.
Time frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
Change From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
Change from baseline in CDAI score at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: Baseline (Week 0) and Week 96
Number of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
Number of participants in clinical response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: At Week 96
Number of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
Number of participants in clinical remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
Time frame: At Week 96
Number of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
Number of participants in endoscopic response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SESCD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: At Week 96
Number of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
Number of participants in endoscopic remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: At Week 96
Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline
Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) during LTE phase among participants receiving oral corticosteroids other than Budesonide at baseline were reported.
Time frame: Baseline (Week 0), Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, and 232
| Milestone | Guselkumab 200 Milligrams (mg) |
|---|---|
| Started | 38 |
| Completed | 36 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Milestone | Guselkumab 200 Milligrams (mg) |
|---|---|
| Started | 33 |
| Lte safety analysis set | 32 |
| Completed | 28 |
| Not completed | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Cd related surgery | 1 |
Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AEs (TEAEs) were AEs with onset during the intervention phase or that were a consequence of a pre-existing condition that had worsened since baseline. All TEAEs including serious and non-serious AEs were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 33 |
Number of participants with TESAEs were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 3 |
Number of participants with TEAESI was reported. Active tuberculosis (TB) or malignancies were considered as TEAESIs. TEAESIs were AESIs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI) | 0 |
Number of participants with treatment-emergent abnormalities in hematology laboratory parameters were reported. Laboratory tests included in hematology were hemoglobin, lymphocytes, neutrophils, platelet count, Total WBC (white blood cell) Count. National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Hemoglobin (increased): Grade 1 | 0 |
| Hemoglobin (increased): Grade 2 | 0 |
| Hemoglobin (increased): Grade 3 | 0 |
| Hemoglobin (increased): Grade 4 | 0 |
| Hemoglobin (decreased): Grade 1 | 18 |
| Hemoglobin (decreased): Grade 2 | 2 |
| Hemoglobin (decreased): Grade 3 | 3 |
| Hemoglobin (decreased): Grade 4 | 0 |
| Lymphocytes (increased): Grade 1 | 0 |
| Lymphocytes (increased): Grade 2 | 0 |
| Lymphocytes (increased): Grade 3 | 0 |
| Lymphocytes (increased): Grade 4 | 0 |
| Lymphocytes (decreased): Grade 1 | 5 |
| Lymphocytes (decreased): Grade 2 | 7 |
| Lymphocytes (decreased): Grade 3 | 4 |
| Lymphocytes (decreased): Grade 4 | 0 |
| Neutrophils (decreased): Grade 1 | 7 |
| Neutrophils (decreased): Grade 2 | 7 |
| Neutrophils (decreased): Grade 3 | 0 |
| Neutrophils (decreased): Grade 4 | 0 |
| Platelets (decreased): Grade 1 | 1 |
| Platelets (decreased): Grade 2 | 0 |
| Platelets (decreased): Grade 3 | 0 |
| Platelets (decreased): Grade 4 | 0 |
| Total WBC Count (increased): Grade 1 | 0 |
| Total WBC Count (increased): Grade 2 | 0 |
| Total WBC Count (increased): Grade 3 | 0 |
| Total WBC Count (increased): Grade 4 | 0 |
| Total WBC Count (decreased): Grade 1 | 9 |
| Total WBC Count (decreased): Grade 2 | 9 |
| Total WBC Count (decreased): Grade 3 | 0 |
| Total WBC Count (decreased): Grade 4 | 0 |
Number of participants with treatment-emergent abnormalities in chemistry laboratory parameters were reported. Laboratory parameters included in clinical chemistry were albumin, corrected calcium, creatinine, glucose, potassium, sodium. NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Albumin (decreased): Grade 1 | 0 |
| Albumin (decreased): Grade 2 | 1 |
| Albumin (decreased): Grade 3 | 0 |
| Albumin (decreased): Grade 4 | 0 |
| Corrected Calcium (increased): Grade 1 | 0 |
| Corrected Calcium (increased): Grade 2 | 0 |
| Corrected Calcium (increased): Grade 3 | 0 |
| Corrected Calcium (increased): Grade 4 | 0 |
| Corrected Calcium (decreased): Grade 1 | 3 |
| Corrected Calcium (decreased): Grade 2 | 0 |
| Corrected Calcium (decreased): Grade 3 | 0 |
| Corrected Calcium (decreased): Grade 4 | 0 |
| Creatinine (increased): Grade 1 | 2 |
| Creatinine (increased): Grade 2 | 1 |
| Creatinine (increased): Grade 3 | 0 |
| Creatinine (increased): Grade 4 | 0 |
| Glucose (decreased): Grade 1 | 1 |
| Glucose (decreased): Grade 2 | 1 |
| Glucose (decreased): Grade 3 | 0 |
| Glucose (decreased): Grade 4 | 0 |
| Potassium (increased): Grade 1 | 0 |
| Potassium (increased): Grade 2 | 1 |
| Potassium (increased): Grade 3 | 0 |
| Potassium (increased): Grade 4 | 0 |
| Potassium (decreased): Grade 1 | 0 |
| Potassium (decreased): Grade 2 | 5 |
| Potassium (decreased): Grade 3 | 0 |
| Potassium (decreased): Grade 4 | 0 |
| Sodium (increased): Grade 1 | 0 |
| Sodium (increased): Grade 2 | 0 |
| Sodium (increased): Grade 3 | 0 |
| Sodium (increased): Grade 4 | 0 |
| Sodium (decreased): Grade 1 | 0 |
| Sodium (decreased): Grade 2 | 0 |
| Sodium (decreased): Grade 3 | 0 |
| Sodium (decreased): Grade 4 | 0 |
Number of participants with TEAEs of infections were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With TEAEs of Infections | 11 |
Number of participants with TEAEs of injection-site reactions were reported. A significant injection-site reaction was defined as an adverse reaction that was manifested through 1 or more of the following symptoms: significant bruising, erythema, hemorrhage, irritation, pain, pruritus at the site of injection. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With TEAEs of Injection-site Reactions | 3 |
Number of participants with TEAEs temporally associated with infusion were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With TEAEs Temporally Associated With Infusion | 0 |
TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. The Columbia-suicide severity rating scale (C-SSRS) defined was 5 subtypes of suicidal ideation and 4 possible suicidal behaviors, as well as non-suicidal self-injurious behavior and completed suicide. The C-SSRS was an investigator-administered questionnaire: 1) No suicidal ideation or behaviors (including self-injurious behavior without suicidal intent): No further action was needed; 2) Suicidal ideation levels 1-3 or non-suicidal self-injurious behavior; participant risk is assessed by the investigator. 3) Suicidal ideation levels 4 or 5 or any suicidal behavior: participant risk assessed and referral to a mental health professional. If no events qualify for scores of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicated greater severity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent | 0 |
Number of participants with clinically significant treatment-emergent abnormalities in vital signs were reported. Vital signs included weight, pulse rate, temperature, respiratory rate, systolic blood pressure, and diastolic blood pressure. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs | 0 |
Number of participants with concomitant medications for Crohn's disease were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Oral amino salicylates | 28 |
| 6- mercaptopurine/azathioprine | 16 |
| oral corticosteroids | 12 |
Number of participants with clinical response through Week 48 were reported. Clinical response was defined as a greater than or equal to (\>=) 100-point reduction from baseline in CDAI score or CDAI score less than (\<) 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | 20 |
| Week 8 | 25 |
| Week 12 | 30 |
| Week 16 | 28 |
| Week 20 | 28 |
| Week 24 | 30 |
| Week 28 | 29 |
| Week 32 | 29 |
| Week 36 | 29 |
| Week 40 | 28 |
| Week 44 | 29 |
| Week 48 | 31 |
Number of participants with clinical remission through Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | 17 |
| Week 8 | 19 |
| Week 12 | 23 |
| Week 16 | 23 |
| Week 20 | 22 |
| Week 24 | 25 |
| Week 28 | 25 |
| Week 32 | 25 |
| Week 36 | 26 |
| Week 40 | 23 |
| Week 44 | 25 |
| Week 48 | 29 |
Number of participants with PRO-2 remission through Week 48 were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | 6 |
| Week 8 | 12 |
| Week 12 | 16 |
| Week 16 | 16 |
| Week 20 | 19 |
| Week 24 | 18 |
| Week 28 | 21 |
| Week 32 | 19 |
| Week 36 | 20 |
| Week 40 | 21 |
| Week 44 | 23 |
| Week 48 | 22 |
Change from baseline in SES-CD score at Week 48 were reported. The SES-CD score was used to evaluate endoscopic improvement. The SES-CD was based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for the narrowing component which only attain a maximum total score of 11 because, the presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| score on a scale | Guselkumab 200 Milligrams (mg) |
|---|---|
| Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48 | -6.4 ± 7.00 |
Serum concentration of guselkumab were reported.
| micrograms/milliliter (mcg/mL) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 0: pre-dose | NA ± NA |
| Week 0: 1 hour post dose | 60.567 ± 7.8417 |
| Week 4: pre-dose | 6.656 ± 2.5431 |
| Week 4: 1 hour post dose | 63.556 ± 10.7183 |
| Week 8: pre-dose | 8.679 ± 3.1697 |
| Week 8: 1 hour post dose | 65.484 ± 7.8536 |
| Week 12: pre-dose | 9.691 ± 4.4559 |
| Week 16: pre-dose | 9.143 ± 4.3351 |
| Week 20: pre-dose | 8.761 ± 4.3497 |
| Week 24: pre-dose | 8.966 ± 4.6369 |
| Week 32: pre-dose | 8.381 ± 3.7270 |
| Week 40: pre-dose | 9.417 ± 5.3775 |
| Week 48: pre-dose | 8.885 ± 4.4065 |
Number of participants with anti-guselkumab antibodies through Week 48 were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Anti-Guselkumab Antibodies Through Week 48 | 1 |
Number of participants with neutralizing-guselkumab antibodies through Week 48 were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Neutralizing-Guselkumab Antibodies Through Week 48 | 0 |
Change from baseline in inflammatory PD marker of CRP concentration were reported.
| milligrams per liter (mg/L) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | -1.65 (-38.90 to -0.15) |
| Week 8 | -2.20 (-36.55 to -0.25) |
| Week 12 | -2.40 (-44.20 to -0.20) |
| Week 16 | -0.90 (-44.10 to -0.30) |
| Week 20 | -0.70 (-45.20 to 0.20) |
| Week 24 | -1.60 (-45.10 to -0.20) |
| Week 32 | -1.25 (-30.50 to -0.40) |
| Week 40 | -1.05 (-31.90 to -0.20) |
| Week 48 | -1.65 (-33.40 to -0.10) |
Change from baseline in inflammatory PD marker of FC levels were reported.
| milligrams per kilogram (mg/kg) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | -270.0 (-817.0 to -45.0) |
| Week 8 | -252.5 (-1614.5 to -79.0) |
| Week 12 | -380.0 (-1563.0 to -110.0) |
| Week 24 | -310.0 (-1722.0 to -87.0) |
| Week 48 | -280.0 (-1678.0 to -123.0) |
Change from baseline in CDAI score at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| score on a scale | Guselkumab 200 Milligrams (mg) |
|---|---|
| <= 1st Quartile Concentration | -171.7 ± 152.12 |
| > 1st Quartile and <= 2nd Quartile Concentration | -137.6 ± 74.78 |
| >2nd Quartile and <= 3rd Quartile Concentration | -157.5 ± 124.85 |
| > 3rd Quartile Concentration | -146.0 ± 111.21 |
Number of participants in clinical response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <= 1st Quartile Concentration | 8 |
| > 1st Quartile and <= 2nd Quartile Concentration | 8 |
| >2nd Quartile and <= 3rd Quartile Concentration | 7 |
| > 3rd Quartile Concentration | 8 |
Number of participants in clinical remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <= 1st Quartile Concentration | 7 |
| > 1st Quartile and <= 2nd Quartile Concentration | 7 |
| >2nd Quartile and <= 3rd Quartile Concentration | 7 |
| > 3rd Quartile Concentration | 8 |
Number of participants in endoscopic response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <= 1st Quartile Concentration | 4 |
| > 1st Quartile and <= 2nd Quartile Concentration | 4 |
| >2nd Quartile and <= 3rd Quartile Concentration | 5 |
| > 3rd Quartile Concentration | 5 |
Number of participants in endoscopic remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <= 1st Quartile Concentration | 2 |
| > 1st Quartile and <= 2nd Quartile Concentration | 3 |
| >2nd Quartile and <= 3rd Quartile Concentration | 4 |
| > 3rd Quartile Concentration | 4 |
Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) through Week 48 among participants receiving oral corticosteroids other than Budesonide at baseline were reported.
| milligram per day (mg/day) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 4 | 0.00 ± 0.000 |
| Week 8 | 0.00 ± 0.000 |
| Week 12 | 0.00 ± 0.000 |
| Week 16 | -9.06 ± 6.722 |
| Week 20 | -13.13 ± 8.509 |
| Week 24 | -13.75 ± 7.500 |
| Week 28 | -13.75 ± 7.500 |
| Week 32 | -13.75 ± 7.500 |
| Week 36 | -13.75 ± 7.500 |
| Week 40 | -13.75 ± 7.500 |
| Week 44 | -13.75 ± 7.500 |
| Week 48 | -13.75 ± 7.500 |
Number of participants not receiving concomitant corticosteroids at Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline | 9 |
Number of participants not receiving concomitant corticosteroids for at least 30 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline | 9 |
Number of participants not receiving concomitant corticosteroids for at least 90 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline | 9 |
Number of participants with clinical response through LTE phase were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 27 |
| Week 144 | 18 |
| Week 192 | 9 |
| Week 240 | 3 |
Number of participants with clinical-biomarker response through LTE phase were reported. Clinical-biomarker response was defined as clinical response based on CDAI score and \>=50% reduction from baseline in CRP or FC. Clinical response: a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug\[s\] and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 24 |
| Week 144 | 18 |
| Week 192 | 9 |
| Week 240 | 3 |
Number of participants with clinical remission through LTE phase were reported. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 27 |
| Week 144 | 16 |
| Week 192 | 8 |
| Week 240 | 3 |
Number of participants in endoscopic response through LTE phase were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score \<=2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 13 |
| Week 144 | 9 |
| Week 192 | 4 |
| Week 240 | 2 |
Number of participants in endoscopic remission through LTE phase were reported. Endoscopic remission was defined as an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing omponent which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 13 |
| Week 144 | 8 |
| Week 192 | 3 |
| Week 240 | 1 |
Number of participants With endoscopic healing through LTE phase were reported. Endoscopic healing was defined as the absence of mucosal ulcerations.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 8 |
| Week 144 | 7 |
| Week 192 | 2 |
| Week 240 | 1 |
Change from baseline in SES-CD score during LTE phase were reported. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| score on a scale | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | -4.9 ± 5.98 |
| Week 144 | -5.1 ± 5.90 |
| Week 192 | -5.1 ± 6.66 |
| Week 240 | -10.7 ± 10.07 |
Number of participants with PRO-2 remission during LTE phase were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96 | 18 |
| Week 144 | 14 |
| Week 192 | 6 |
| Week 240 | 2 |
Number of participants with any Crohn's Disease-related hospitalizations and/or surgeries during the study were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study | 0 |
Serum guselkumab concentrations during LTE phase were reported.
| mcg/mL | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 96: pre dose | 9.308 ± 4.7275 |
| Week 144: pre dose | 8.886 ± 3.7197 |
| Week 192: pre dose | 8.819 ± 3.5263 |
| Week 240: pre dose | 6.765 ± 0.9600 |
Number of participants with anti-guselkumab antibodies during the study were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Anti-Guselkumab Antibodies During the Study | 5 |
Number of participants with neutralizing-guselkumab antibodies during the study were reported.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| Number of Participants With Neutralizing Antibodies to Guselkumab During the Study | 0 |
Change from baseline in inflammatory PD marker of CRP concentration during LTE phase were reported.
| mg/L | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 64 | -2.45 (-32.45 to -0.10) |
| Week 80 | -2.30 (-32.80 to -0.15) |
| Week 96 | -1.60 (-45.10 to -0.20) |
| Week 112 | -2.30 (-27.60 to -0.10) |
| Week 128 | -2.90 (-47.70 to -0.40) |
| Week 144 | -2.60 (-44.20 to -0.30) |
| Week 160 | -7.40 (-50.70 to -1.25) |
| Week 176 | -11.10 (-52.10 to -0.90) |
| Week 192 | -14.90 (-52.50 to -0.80) |
| Week 208 | -15.00 (-49.10 to -0.75) |
| Week 224 | -5.80 (-25.45 to -0.10) |
| Week 240 | -11.20 (-41.70 to -0.90) |
Change from baseline in inflammatory PD marker of FC levels during LTE phase were reported.
| mg/L | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 64 | -281.0 (-1690.0 to -114.0) |
| Week 80 | -339.5 (-1816.5 to -134.5) |
| Week 96 | -337.0 (-1912.0 to -138.0) |
| Week 112 | -319.0 (-1819.0 to -138.0) |
| Week 128 | -319.0 (-2616.0 to -155.0) |
| Week 144 | -270.0 (-2624.0 to -158.0) |
| Week 160 | -660.0 (-1885.0 to -203.0) |
| Week 176 | -1619.0 (-5306 to -155) |
| Week 192 | -1579.5 (-2804.0 to -319.0) |
| Week 208 | -1684.0 (-1903.0 to -230.0) |
| Week 224 | -1625.0 (-2449.0 to -811.0) |
| Week 240 | -1955.0 (-3057.0 to -1322.0) |
Change from baseline in CDAI score at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| score on a scale | Guselkumab 200 Milligrams (mg) |
|---|---|
| <=1st Quartile Concentration | -155.3 ± 118.52 |
| >1st Quartile and <=2nd Quartile Concentration | -140.3 ± 127.35 |
| >2nd Quartile and <=3rd Quartile Concentration | -208.5 ± 144.33 |
| >3rd Quartile Concentration | -152.0 ± 105.49 |
Number of participants in clinical response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <=1st Quartile Concentration | 7 |
| >1st Quartile and <=2nd Quartile Concentration | 5 |
| >2nd Quartile and <=3rd Quartile Concentration | 8 |
| >3rd Quartile Concentration | 7 |
Number of participants in clinical remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <=1st Quartile Concentration | 7 |
| >1st Quartile and <=2nd Quartile Concentration | 5 |
| >2nd Quartile and <=3rd Quartile Concentration | 8 |
| >3rd Quartile Concentration | 7 |
Number of participants in endoscopic response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SESCD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| <=1st Quartile Concentration | 4 |
| >1st Quartile and <=2nd Quartile Concentration | 4 |
| >2nd Quartile and <=3rd Quartile Concentration | 3 |
| >3rd Quartile Concentration | 2 |
Number of participants in endoscopic remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Participants | Guselkumab 200 Milligrams (mg) |
|---|---|
| >1st Quartile Concentration | 4 |
| >1st Quartile and <=2nd Quartile Concentration | 4 |
| >2nd Quartile and <=3rd Quartile Concentration | 3 |
| >3rd Quartile Concentration | 2 |
Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) during LTE phase among participants receiving oral corticosteroids other than Budesonide at baseline were reported.
| mg/day | Guselkumab 200 Milligrams (mg) |
|---|---|
| Week 52 | -13.75 ± 7.500 |
| Week 56 | -13.75 ± 7.500 |
| Week 60 | -15.00 ± 8.660 |
| Week 64 | -13.75 ± 7.500 |
| Week 68 | -15.00 ± 8.660 |
| Week 72 | -13.75 ± 7.500 |
| Week 76 | -15.00 ± 8.660 |
| Week 80 | -13.75 ± 7.500 |
| Week 84 | -15.00 ± 8.660 |
| Week 88 | -13.75 ± 7.500 |
| Week 92 | -13.75 ± 7.500 |
| Week 96 | -13.75 ± 7.500 |
| Week 100 | -13.75 ± 7.500 |
| Week 104 | -13.75 ± 7.500 |
| Week 108 | -13.75 ± 7.500 |
| Week 112 | -13.75 ± 7.500 |
| Week 116 | -13.75 ± 7.500 |
| Week 120 | -13.75 ± 7.500 |
| Week 124 | -13.75 ± 7.500 |
| Week 128 | -13.75 ± 7.500 |
| Week 132 | -13.75 ± 7.500 |
| Week 136 | -13.75 ± 7.500 |
| Week 140 | -13.75 ± 7.500 |
| Week 144 | -13.75 ± 7.500 |
| Week 148 | -13.75 ± 7.500 |
| Week 152 | -13.75 ± 7.500 |
| Week 156 | -13.75 ± 7.500 |
| Week 160 | -13.75 ± 7.500 |
| Week 164 | -13.75 ± 7.500 |
| Week 168 | -13.75 ± 7.500 |
| Week 172 | -11.67 ± 7.638 |
| Week 176 | -11.67 ± 7.638 |
| Week 180 | -11.67 ± 7.638 |
| Week 184 | -11.67 ± 7.638 |
| Week 188 | -11.67 ± 7.638 |
| Week 192 | -11.67 ± 7.638 |
| Week 196 | -11.67 ± 7.638 |
| Week 200 | -11.67 ± 7.638 |
| Week 204 | -11.67 ± 7.638 |
| Week 208 | -11.67 ± 7.638 |
| Week 212 | -15.00 ± 7.071 |
| Week 216 | -11.67 ± 7.638 |
| Week 220 | -15.00 ± 7.071 |
| Week 224 | -20.00 ± NA |
| Week 228 | -20.00 ± NA |
| Week 232 | -20.00 ± NA |
Collected over All cause mortality (Open-label phase [OL phase]): From screening (Week -8) up to Week 48; All cause mortality (LTE phase): From Week 48 up to Week 248. SAEs and Other AEs: From baseline (Week 0) up to Week 48; SAEs and Other AEs (LTE phase): From Week 48 up to Week 248. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Phase: Guselkumab 200 mg | 0/38 (0%) | 3/38 (7.9%) | 30/38 (78.9%) |
| LTE Phase: Guselkumab 200 mg | 0/32 (0%) | 10/32 (31.3%) | 32/32 (100%) |
| Event | Open Label Phase: Guselkumab 200 mg | LTE Phase: Guselkumab 200 mg |
|---|---|---|
| VertigoEar and labyrinth disorders | 0/38 | 1/32 |
| Anogenital DysplasiaGastrointestinal disorders | 0/38 | 1/32 |
| Crohn's DiseaseGastrointestinal disorders | 0/38 | 1/32 |
| Ileal StenosisGastrointestinal disorders | 0/38 | 1/32 |
| Intestinal Mucosal TearGastrointestinal disorders | 0/38 | 1/32 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/38 | 1/32 |
| Small Intestinal StenosisGastrointestinal disorders | 0/38 | 1/32 |
| Colorectal AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 1/32 |
| MyelopathyNervous system disorders | 0/38 | 1/32 |
| UreterolithiasisRenal and urinary disorders | 0/38 | 1/32 |
| Event | Open Label Phase: Guselkumab 200 mg | LTE Phase: Guselkumab 200 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/38 | 17/32 |
| PyrexiaGeneral disorders | 15/38 | 6/32 |
| Covid-19Infections and infestations | 1/38 | 8/32 |
| Back PainMusculoskeletal and connective tissue disorders | 2/38 | 6/32 |
| HeadacheNervous system disorders | 6/38 | 5/32 |
| Coronavirus InfectionInfections and infestations | 0/38 | 3/32 |
| InfluenzaInfections and infestations | 0/38 | 3/32 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 2/38 | 3/32 |
| DiarrhoeaGastrointestinal disorders | 1/38 | 2/32 |
| ProctitisGastrointestinal disorders | 0/38 | 2/32 |
| Age, Continuous(years) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Mean | 42.0 ± 14.58 |
| Sex: Female, Male(Participants) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Female | 14 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 38 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Guselkumab 200 Milligrams (mg) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 38 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Guselkumab 200 Milligrams (mg) |
|---|---|
| Japan | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jun 2020 to primary completion in Feb 2024, 44 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab